​AmeriHealth is updating our position on laparoscopic (i.e., Acessa^®) and transcervical (i.e., Sonata^®) radiofrequency ablation from Experimental/Investigational to Medically Necessary for AmeriHealth and AmeriHealth Administrators members.

For detailed information, please refer to Medical Policy #11.06.10: Laparoscopic, Percutaneous, and Transcervical Techniques for Uterine Fibroid Myolysis, which is effective June 6, 2022.